Core signaling pathways in human pancreatic cancers revealed by global genomic analyses S Jones, X Zhang, DW Parsons, JCH Lin, RJ Leary, P Angenendt, ... science 321 (5897), 1801-1806, 2008 | 4688 | 2008 |
The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018 | 4629 | 2018 |
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target C Grávalos, A Jimeno Annals of oncology 19 (9), 1523-1529, 2008 | 1477 | 2008 |
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ... The Lancet 393 (10167), 156-167, 2019 | 1422 | 2019 |
Patient-derived tumour xenografts as models for oncology drug development JJ Tentler, AC Tan, CD Weekes, A Jimeno, S Leong, TM Pitts, JJ Arcaroli, ... Nature reviews Clinical oncology 9 (6), 338-350, 2012 | 1402 | 2012 |
Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy Q Huang, F Li, X Liu, W Li, W Shi, FF Liu, B O'sullivan, Z He, Y Peng, ... Nature medicine 17 (7), 860-866, 2011 | 922 | 2011 |
Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology DG Pfister, S Spencer, D Adelstein, D Adkins, Y Anzai, DM Brizel, ... Journal of the National Comprehensive Cancer Network 18 (7), 873-898, 2020 | 867 | 2020 |
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers G Feldmann, S Dhara, V Fendrich, D Bedja, R Beaty, M Mullendore, ... Cancer research 67 (5), 2187-2196, 2007 | 854 | 2007 |
Head and neck cancers, version 2.2014 DG Pfister, S Spencer, DM Brizel, B Burtness, PM Busse, JJ Caudell, ... Journal of the National Comprehensive Cancer Network 12 (10), 1454-1487, 2014 | 730 | 2014 |
NCCN guidelines insights: head and neck cancers, version 1.2018 AD Colevas, SS Yom, DG Pfister, S Spencer, D Adelstein, D Adkins, ... Journal of the National Comprehensive Cancer Network 16 (5), 479-490, 2018 | 570 | 2018 |
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma ZA Rasheed, J Yang, Q Wang, J Kowalski, I Freed, C Murter, SM Hong, ... Journal of the National Cancer Institute 102 (5), 340-351, 2010 | 532 | 2010 |
An in vivo platform for translational drug development in pancreatic cancer B Rubio-Viqueira, A Jimeno, G Cusatis, X Zhang, C Iacobuzio-Donahue, ... Clinical cancer research 12 (15), 4652-4661, 2006 | 496 | 2006 |
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101Clinical Response in NTRK-Fusion Sarcoma RC Doebele, LE Davis, A Vaishnavi, AT Le, A Estrada-Bernal, S Keysar, ... Cancer discovery 5 (10), 1049-1057, 2015 | 410 | 2015 |
Comprehensive molecular characterization of the hippo signaling pathway in cancer Y Wang, X Xu, D Maglic, MT Dill, K Mojumdar, PKS Ng, KJ Jeong, ... Cell reports 25 (5), 1304-1317. e5, 2018 | 380 | 2018 |
NCCN guidelines insights: head and neck cancers, version 2.2017 D Adelstein, ML Gillison, DG Pfister, S Spencer, D Adkins, DM Brizel, ... Journal of the National Comprehensive Cancer Network 15 (6), 761-770, 2017 | 349 | 2017 |
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development A Jimeno, G Feldmann, A Suárez-Gauthier, Z Rasheed, A Solomon, ... Molecular cancer therapeutics 8 (2), 310-314, 2009 | 336 | 2009 |
NCCN Guidelines® insights: Head and neck cancers, version 1.2022: Featured updates to the NCCN guidelines JJ Caudell, ML Gillison, E Maghami, S Spencer, DG Pfister, D Adkins, ... Journal of the National Comprehensive Cancer Network 20 (3), 224-234, 2022 | 278 | 2022 |
Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer I Garrido-Laguna, M Uson, NV Rajeshkumar, AC Tan, E De Oliveira, ... Clinical Cancer Research 17 (17), 5793-5800, 2011 | 274 | 2011 |
Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28 PN Le, JD McDermott, A Jimeno Pharmacology & therapeutics 146, 1-11, 2015 | 272 | 2015 |
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection A Jimeno, WA Messersmith, FR Hirsch, WA Franklin, SG Eckhardt Journal of Clinical Oncology 27 (7), 1130-1136, 2009 | 271 | 2009 |